These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20667585)

  • 21. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
    Mani H; Lindhoff-Last E
    Pharm Unserer Zeit; 2009; 38(4):342-50. PubMed ID: 19572355
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention of thrombosis during pregnancy.
    Vilela VS; de Jesús NR; Levy RA
    Isr Med Assoc J; 2002 Oct; 4(10):794-7. PubMed ID: 12389343
    [No Abstract]   [Full Text] [Related]  

  • 23. What next for low dose aspirin?
    Morgan G
    J Epidemiol Community Health; 2005 Jan; 59(1):3-4. PubMed ID: 15598718
    [No Abstract]   [Full Text] [Related]  

  • 24. Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification.
    Patti G; Di Sciascio G
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):128-34. PubMed ID: 19670304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding.
    May AE; Geisler T; Gawaz M
    Thromb Haemost; 2008 Mar; 99(3):487-93. PubMed ID: 18327396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
    Mooe T
    Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
    [No Abstract]   [Full Text] [Related]  

  • 27. Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
    Walker CW; Dawley CA; Fletcher SF
    Am Fam Physician; 2007 Dec; 76(11):1643-5. PubMed ID: 18092705
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer.
    Salman MC; Ayhan A
    Med Hypotheses; 2006; 66(6):1179-81. PubMed ID: 16446052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery.
    Cholette JM; Rubenstein JS; Alfieris GM; McDermott MP; Harmon WG; Vermilion R; Eaton MP; Gangemi JJ; Lerner NB
    Ann Thorac Surg; 2007 Oct; 84(4):1320-5. PubMed ID: 17888990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
    Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
    Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat.
    Herbert JM; Bernat A; Samama M; Maffrand JP
    Thromb Haemost; 1996 Jul; 76(1):94-8. PubMed ID: 8819259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of thrombo-elastography in the monitoring of aspirin therapy.
    Mayne E; Jacobson B; Louw S; Bernstein P; Mayne A
    S Afr Med J; 2007 Dec; 97(12):1289-91. PubMed ID: 18264612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel mechanisms of aspirin pharmacologic actions: a model for studying herbal natural products.
    Wu KK
    Thromb Res; 2005; 117(1-2):61-4; discussion 65-7. PubMed ID: 16045971
    [No Abstract]   [Full Text] [Related]  

  • 35. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of thrombosis in hip alloplasty].
    Borris LC; Petersen MB; Lassen MR
    Ugeskr Laeger; 2001 Feb; 163(7):934; discussion 934-5. PubMed ID: 11228793
    [No Abstract]   [Full Text] [Related]  

  • 38. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
    Kuliczkowski W; Witkowski A; Polonski L; Watala C; Filipiak K; Budaj A; Golanski J; Sitkiewicz D; Pregowski J; Gorski J; Zembala M; Opolski G; Huber K; Arnesen H; Kristensen SD; De Caterina R
    Eur Heart J; 2009 Feb; 30(4):426-35. PubMed ID: 19174428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management.
    Zuern CS; Lindemann S; Gawaz M
    Semin Thromb Hemost; 2009 Apr; 35(3):295-306. PubMed ID: 19452405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.